Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Five Big Winners in Today’s Trading Session Include Biotech with Promising Drug That Cures Ebola-like Virus

Page 1 of 2

U.S equities inched lower in early trading this morning following twin deadly attacks on Brussels’ Zaventem airport and a metro train in the Belgian capital. Airlines, travel booking sites and other travel-related stocks have been among the biggest losers thus far in today’s trading session as a result. Nonetheless, there are a few stocks that have bucked the trend and made strong upward moves today. This article will discuss five of the biggest winners in today’s trading session and the firm-specific developments that are pushing those stocks higher.

At Insider Monkey, we track around 785 hedge funds and institutional investors. Through extensive backtests, we have determined that imitating some of the stocks that these investors are collectively bullish on can help retail investors generate double digits of alpha per year. The key is to focus on the small-cap picks of these funds, which are usually less followed by the broader market and allow for larger price inefficiencies (see more details about our small-cap strategy).

Let’s begin our discussion with Akorn Inc. (NASDAQ:AKRX). The generic drugmaker has seen its shares surge by more than 39% so far today, after the company reported preliminary unaudited 2015 financial results and issued its financial guidance for 2016. Akorn has not filed its quarterly 10-K filings with the SEC since last spring, as the company has been working on restating earnings for the final three quarters of 2014. To be more detailed, the company’s accounting issues are related to its acquisition of Hi-Tech in April 2014, with the firm discovering an accounting error that was connected with the fair value allocation of assets acquired and liabilities assumed from that deal. As previously discussed, Akorn Inc. (NASDAQ:AKRX) estimates that revenue and pretax income from continuing operations were overstated by $35 million for the full 2014 year. Going back to the freshly-revealed preliminary unaudited financial results, the company’s preliminary net revenue for 2015 is expected to be roughly $985 million, while GAAP diluted earnings per share is anticipated to be $1.14. The company anticipates net revenue in the range of $1.06 billion to $1.08 billion for 2016 and GAAP diluted EPS in the range of $1.56 to $1.66. Shares of Akorn are down by 47% over the past 12 months. John Paulson’s Paulson & Co. acquired a new stake of 2.88 million shares in Akorn Inc. (NASDAQ:AKRX) in the final quarter of 2015.

Follow Akorn Inc (NASDAQ:AKRX)
Trade (NASDAQ:AKRX) Now!

Shares of Centrus Energy Corp (NYSEMKT:LEU) jumped by 29% in morning trading after the company released its fourth-quarter earnings report. Centrus Energy is a supplier of low enriched uranium, which is a key component in the production of nuclear fuel for reactors to produce electricity. The long-term provider of LEU reported fourth-quarter revenue of $157.9 million, which was an increase of 28% year-over-year. Nonetheless, revenue for 2015 shrank by 19% year-over-year to $418.2 million, which reflects the previously-anticipated reduction in the volume of separative work units, which is contained in the LEU, and the expiration of the company’s technology services contract as of the end of September 2015. Centrus Energy Corp (NYSEMKT:LEU) also reported a net loss of $101.8 million for the fourth quarter, far worse than the net loss of $42.3 million reported for the same quarter of the prior year. The company had a net loss of $187.4 million in 2015, compared to net income of $297.8 million in 2014. The 2015 bottom-line figure includes an impairment of excess reorganization value, while the 2014 results include $425.4 million of net reorganization gains. Shares of Centrus Energy are up by a whopping 133% year-to-date, following the company’s announcement of newly-signed sales contracts to supply utility customers with enriched uranium fuel. Those contracts have an approximate value of $165 million, with deliveries through 2022. Glenn Russell Dubin’s Highbridge Capital Management owns 371,475 shares of Centrus Energy Corp (NYSEMKT:LEU) as of December 31.

Follow Centrus Energy Corp (NYSEMKT:LEU)
Trade (NYSEMKT:LEU) Now!

The next page of this article will discuss the three other big winners in today’s trading session.

Page 1 of 2
Loading Comments...